ReviewCalcified tissue international2023
Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging.
Review in Calcified tissue international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Grape Consumption to Improve Muscle Strength and Cognitive Function
Multimodal Approach to Sarcopenia and Its Prognostic Impact in Older Patients Hospitalized for Acute Heart Failure (MUSICA Study).
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Pooled it
- Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review.Journal of translational medicine · 2025Pooled it
- Influence of Klotho Protein Levels in Obesity and Sarcopenia: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map.Calcified tissue international · 2026Review
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
- The impact of serum myokine profile on the outcome of peritoneal dialysis patients.BMC nephrology · 2026Article
- The decision support system for preventing non-elderly sarcopenia: Data from NHANES 2011-2018.Sports medicine and health science · 2026Article
- Candidate Circulating microRNAs in Patients with Sarcopenic Obesity: Results of a Pilot Screening.Biomedicines · 2026Article
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.Metabolites · 2026Review
- An exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.Aging clinical and experimental research · 2026Article
- Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Intramuscular fat content and the risk of peritonitis in peritoneal dialysis patients.Clinical kidney journal · 2026Article
- Prediabetes Associates With Musculoskeletal Alterations Independent of Total Body Adiposity.Journal of cachexia, sarcopenia and muscle · 2026Article
- Longitudinal study on the relationship between extracellular water distribution changes and muscle mass in severe sarcopenia patients using multi-frequency bioelectrical impedance analysis combined with phase angle measurements.European geriatric medicine · 2026Article
- Creatinine, leucine, and tetrahydrocorticosterone emerge as potential biomarkers for the diagnosis of sarcopenic osteoarthritis in middle-aged and elderly individuals: a cross-sectional exploratory study.Frontiers in molecular biosciences · 2026Article
- Association between muscle-specific strength and inflammatory biomarkers in community-dwelling older women: a cross-sectional study.Scientific reports · 2025Article
- Musculoskeletal biomarkers in health and disease: implications for the aging spine-a review for spinal surgeons by the SRS adult spinal deformity task force on senescence.Spine deformity · 2025Review
- Irisin, Brain-Derived Neurotrophic Factor (BDNF), and Redox Balance in Geriatric Dynapenia.Antioxidants (Basel, Switzerland) · 2025Article
- Establishing Blood-Based Biomarkers for Sarcopenia: Current Challenges and Future Directions.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Plasma biomarkers for monitoring muscle function and physical performance decline in older adults: A 2-year longitudinal study.The journal of nutrition, health & aging · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 12 institutions in 12 countries.
Funding
Abstract
In clinical trials, biochemical markers provide useful information on the drug's mode of action, therapeutic response and side effect monitoring and can act as surrogate endpoints. In pharmacological intervention development for sarcopenia management, there is an urgent need to identify biomarkers to measure in clinical trials and that could be used in the future in clinical practice. The objective of the current consensus paper is to provide a clear list of biochemical markers of musculoskeletal health and aging that can be recommended to be measured in Phase II and Phase III clinical trials evaluating new chemical entities for sarcopenia treatment. A working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) proposed classifying biochemical markers into 2 series: biochemical markers evaluating musculoskeletal status and biochemical markers evaluating causal factors. For series 1, the group agreed on 4 biochemical markers that should be assessed in Phase II or Phase III trials (i.e., Myostatin-Follistatin, Brain Derived Neurotrophic Factor, N-terminal Type III Procollagen and Serum Creatinine to Serum Cystatin C Ratio - or the Sarcopenia Index). For series 2, the group agreed on 6 biochemical markers that should be assessed in Phase II trials (i.e., the hormones insulin-like growth factor-1 (IGF-I), dehydroepiandrosterone sulphate, and cortisol, and the inflammatory markers C-reactive protein (CRP), interleukin-6 and tumor necrosis factor-α), and 2 in Phase III trials (i.e., IGF-I and CRP). The group also proposed optional biochemical markers that may provide insights into the mode of action of pharmacological therapies. Further research and development of new methods for biochemical marker assays may lead to the evolution of these recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.